Condition: Oligometastatic Prostate Cancer · Sponsor: British Columbia Cancer Agency
We will investigate whether ultrahypofractionation using stereotactic ablative radiotherapy (SABR) or brachytherapy is as well-tolerated as moderately hypofractionated external beam radiotherapy (EBRT) for treating the prostate in patients with oligometastatic prostate cancer. Secondary aims include assessment of progression-free survival (PFS) and overall survival (OS) as well as cost-effectiveness. We hypothesize that ultrahypofractionation will maintain favorable toxicity profiles and quality of life while achieving comparable or better efficacy, thereby providing a convenient and cost-effective alternative to moderately hypofractionated EBRT.
This description comes directly from the study's public registry record.
Juanita Crook, MD · 250 712 3958 · jcrook@bccancer.bc.ca
Always discuss trial participation with your own doctor first.
| British Columbia Cancer Agency Center for the Southern Interior | Kelowna, British Columbia, Canada | Recruiting |
| Fraser Valley Cancer Center | Surrey, British Columbia, Canada | Not Yet Recruiting |
| Vancouver Cancer Center | Vancouver, British Columbia, Canada | Recruiting |
| Vancouver Island Cancer Center | Victoria, British Columbia, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04610372